Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Core and Main Inc (CNM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Core and Main Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Core and Main Inc trades at $45.41 (market cap $8.56B). The key difference: Core and Main Inc is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Core and Main Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | CNM | |
|---|---|---|
Market Cap | $4.49B | $8.56B |
Sector | Health | Technology |
52-Week High | $28.06 | $66.98 |
52-Week Low | $20.06 | $44.29 |
Enterprise Value | $3.69B | $10.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Core & Main (CNM) trades at $45.98, up 2.34% with recent earnings beats driving positive momentum. The stock shows bearish technical signals with resistance at $46-$48, while fundamentals remain solid with 23.73% ROE and consistent revenue growth. Recent Q1 2026 results exceeded expectations at $0.72 EPS versus $0.70 estimate, supported by strong municipal demand and margin expansion initiatives. The company maintains stable cash flow generation with $655M operating cash flow projected for 2026.
CNM presents a mixed outlook with strong fundamentals offset by technical weakness. The bullish analyst consensus (57% buy ratings) and improving debt profile support upside potential, but near-term price pressure from bearish technical indicators requires caution. Key risks include residential market softness and industry supply chain challenges, though the company's reaffirmed FY26 guidance of $7.8-7.9B revenue provides stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Core and Main Inc
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →
